Cerebral Small Vessel Disease-Induced Apolipoprotein E Leakage Is Associated With Alzheimer Disease and the Accumulation of Amyloid &bgr;-Protein in Perivascular Astrocytes

Apolipoprotein E (apoE) plays a role in the pathogenesis of Alzheimer disease (AD). It is involved in the receptor-mediated cellular clearance of the amyloid &bgr;-protein (A&bgr;) and in the perivascular drainage of the extracellular fluid. Microvascular changes are also associated with AD and have been discussed as a possible reason for altered perivascular drainage. To further clarify the role of apoE in the perivascular and vascular pathology in AD patients, we studied its occurrence and distribution in the perivascular space, the perivascular neuropil, and in the vessel wall of AD and control cases with and without small vessel disease (SVD). Apolipoprotein E was found in the perivascular space and in the neuropil around arteries of the basal ganglia from control and AD cases disclosing no major differences. Western blot analysis of basal ganglia tissue also revealed no significant differences pertaining to the amount of full-length and C-terminal truncated apoE in AD cases compared with controls. In contrast, A&bgr; occurred in apoE-positive perivascular astrocytes in AD cases but not in controls. In blood vessels, apoE and immunoglobulin G were detected within the SVD-altered vessel wall. The severity of SVD was associated with the occurrence of apoE in the vessel wall and with that of A&bgr; in perivascular astrocytes. These results point to an important role of apoE in the perivascular clearance of A&bgr; in the human brain. The occurrence of apoE and immunoglobulin G in SVD lesions and in the perivascular space suggests that the presence of SVD results in plasma-protein leakage into the brain. It is therefore tempting to speculate that apoE represents a pathogenetic link between SVD and AD.

[1]  Dietmar Rudolf Thal,et al.  Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances , 2009, Neurobiology of Aging.

[2]  D. Amaral,et al.  The Hippocampal Formation , 2009 .

[3]  G. Lembo,et al.  β-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension , 2009, Neurobiology of Aging.

[4]  T. Dawson.  Faculty Opinions recommendation of A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. , 2008 .

[5]  C. Johanson,et al.  Apolipoprotein E, Amyloid-&bgr;, and Blood-Brain Barrier Permeability in Alzheimer Disease , 2008, Journal of neuropathology and experimental neurology.

[6]  T. Südhof,et al.  A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides , 2008, Nature Neuroscience.

[7]  T. Terasaki,et al.  Cerebral clearance of human amyloid‐β peptide (1–40) across the blood–brain barrier is reduced by self‐aggregation and formation of low‐density lipoprotein receptor‐related protein‐1 ligand complexes , 2007, Journal of neurochemistry.

[8]  A. Goate,et al.  Clearance of amyloid-β by circulating lipoprotein receptors , 2007, Nature Medicine.

[9]  M. Staufenbiel,et al.  Occurrence and co-localization of amyloid β-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice , 2007, Neurobiology of Aging.

[10]  T. Berzin,et al.  Microvascular injury and blood–brain barrier leakage in Alzheimer's disease , 2007, Neurobiology of Aging.

[11]  M. D'Andrea,et al.  Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons , 2007, Brain Research.

[12]  N. Plesnila,et al.  Characterization of microvascular basal lamina damage and blood–brain barrier dysfunction following subarachnoid hemorrhage in rats , 2007, Brain Research.

[13]  R. Green,et al.  APOE, vascular pathology, and the AD brain , 2005, Neurology.

[14]  H. Braak,et al.  The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease‐related pathology , 2005, Neuropathology and applied neurobiology.

[15]  Dipak P. Ramji,et al.  The key role of apolipoprotein E in atherosclerosis , 2005, Journal of Molecular Medicine.

[16]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[17]  Thomas Wisniewski,et al.  A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice , 2004 .

[18]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[19]  Tony Wyss-Coray,et al.  Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.

[20]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[21]  O. Wiestler,et al.  Vascular Pathology in Alzheimer Disease: Correlation of Cerebral Amyloid Angiopathy and Arteriosclerosis/Lipohyalinosis with Cognitive Decline , 2003, Journal of neuropathology and experimental neurology.

[22]  D. Hui,et al.  Apolipoprotein E Binding to Low Density Lipoprotein Receptor-related Protein-1 Inhibits Cell Migration via Activation of cAMP-dependent Protein Kinase A* , 2003, Journal of Biological Chemistry.

[23]  Sascha Weggen,et al.  The cytoplasmic domain of the LDL receptor‐related protein regulates multiple steps in APP processing , 2002, The EMBO journal.

[24]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[25]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[26]  R. Mahley,et al.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Fullerton,et al.  Impairment of the Blood–Nerve and Blood–Brain Barriers in Apolipoprotein E Knockout Mice , 2001, Experimental Neurology.

[28]  H. Braak,et al.  Sequence of Aβ‐Protein Deposition in the Human Medial Temporal Lobe , 2000 .

[29]  D. Hui,et al.  Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[30]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[31]  M. Breteler,et al.  Vascular factors and Alzheimer disease. , 1999, Alzheimer disease and associated disorders.

[32]  B. Sommer,et al.  Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R N Kalaria,et al.  Overlap between pathology of Alzheimer disease and vascular dementia. , 1999, Alzheimer disease and associated disorders.

[34]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[35]  Yu-Min Kuo,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.

[36]  Y. Ihara,et al.  Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. , 1998, The American journal of pathology.

[37]  Y. Ihara,et al.  Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques , 1998, Acta Neuropathologica.

[38]  H. Braak,et al.  Improved method facilitates reliable APOE genotyping of genomic DNA extracted from formaldehyde-fixed pathology specimens , 1998, Journal of Neuroscience Methods.

[39]  J. Hardy,et al.  Increased Aβ42(43) from cell lines expressing presenilin 1 mutations , 1998, Annals of neurology.

[40]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[42]  M. Tapner,et al.  Soluble Low Density Lipoprotein Receptor-related Protein (LRP) Circulates in Human Plasma* , 1997, The Journal of Biological Chemistry.

[43]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[44]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[45]  S. M. Sumi,et al.  Amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: Predominance of Aβ42(43) , 1996 .

[46]  P. Mcgeer,et al.  Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of β-amyloid protein , 1996, Neuroscience Letters.

[47]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[48]  H. Braak,et al.  Silver Labeling of Alzheimer Neurofibrillary Changes and Brain β-Amyloid , 1993 .

[49]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[50]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.

[51]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[52]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[53]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[55]  H. Braak,et al.  The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases , 1992, Neuroscience Research.

[56]  K. Ikeda,et al.  Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer's disease , 1992, Neuroscience Letters.

[57]  J. Vonsattel,et al.  Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study , 1991, Annals of neurology.

[58]  PhilipR. Wenham,et al.  Apolipoprotein E genotyping by one-stage PCR , 1991, The Lancet.

[59]  G. Persijn,et al.  Results of acute heart retransplantation , 1991, The Lancet.

[60]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[61]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[62]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[63]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[64]  R. Mahley,et al.  Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. , 1987, Biochimica et biophysica acta.

[65]  A. Brun,et al.  A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study , 1986, Annals of neurology.

[66]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[67]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[68]  F. Shimizu,et al.  Identification of components of immunoglobulins in senile plaques by means of fluorescent antibody technique , 1975, Acta Neuropathologica.

[69]  A. Goate,et al.  Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.

[70]  T. Robinson,et al.  Chapter 48 – The Brain in Hypertension , 2007 .

[71]  B. Winblad,et al.  Perivascular deposits of serum proteins in cerebral cortex in vascular dementia , 2004, Acta Neuropathologica.

[72]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[73]  D. Holtzman,et al.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. , 2004, The American journal of pathology.

[74]  Ricardo Insausti,et al.  CHAPTER 23 – Hippocampal Formation , 2004 .

[75]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.

[76]  H. Braak,et al.  Sequence of Abeta-protein deposition in the human medial temporal lobe. , 2000, Journal of neuropathology and experimental neurology.

[77]  H. Braak,et al.  Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. , 2000, Acta neuropathologica.

[78]  H. Braak,et al.  Amyloid β-protein (Aβ)-containing astrocytes are located preferentially near N-terminal-truncated Aβ deposits in the human entorhinal cortex , 2000, Acta Neuropathologica.

[79]  D. Thal,et al.  Diffuse plaques in the molecular layer show intracellular A beta(8-17)-immunoreactive deposits in subpial astrocytes. , 1999, Clinical neuropathology.

[80]  R O Weller,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.

[81]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. , 1997, Nature genetics.

[82]  S. M. Sumi,et al.  Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). , 1996, Annals of neurology.

[83]  Dc Washington.  Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .

[84]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[85]  J. Paton,et al.  THE BRAIN IN HYPERTENSION , 2022 .